Rejoni’s FDA-Approved Juveena Hydrogel Makes Commercial Debut in Fertility Procedure

0
19
John Nealon

BURLINGTON, Mass.–Rejoni Inc. has marked a milestone in the commercial rollout of its FDA-approved Juveena Hydrogel System, with a New Jersey fertility specialist completing the first procedure using the technology to help prevent the recurrence of uterine scar tissue.

Dr. Serena H. Chen, Founding Partner and Director of Advocacy at CCRM Fertility of New Jersey, performed the procedure at the clinic in Livingston, New Jersey.

The Juveena Hydrogel System is a bioabsorbable material developed to reduce the reformation of intrauterine adhesions following hysteroscopic adhesiolysis, a surgical procedure that removes scar tissue from inside the uterus.

Intrauterine adhesions are associated with Asherman’s syndrome, a condition that can develop when the uterine lining is damaged during procedures such as hysteroscopic surgery or uterine curettage. The adhesions can lead to infertility, repeated miscarriages, changes in menstruation and complications during pregnancy.

Although surgery remains the standard treatment for removing uterine adhesions, scar tissue frequently returns, particularly in patients with moderate-to-severe cases. Some women require multiple procedures before attempting pregnancy.

“Performing the first Juveena case was a meaningful moment for our team and for our patients,” said Chen. “The Juveena hydrogel procedure was simple to complete at the end of the hysteroscopy and fit into our existing workflow. For women with intrauterine adhesions, the surgery is only half the battle. Adhesions that come back after adhesiolysis can mean more surgery, more delays, and lost time for patients who often do not have time to lose. Having an FDA-approved option backed by randomized controlled trial data is an important step toward reducing both how often adhesions recur and how severe they are when they do.”

The hydrogel is designed to provide a temporary, absorbable barrier following surgery, helping reduce the likelihood that adhesions will develop again. Its FDA approval was supported by randomized controlled trial data examining adhesion recurrence and severity.

For reproductive specialists, preventing the return of scar tissue is an important consideration because repeated procedures can prolong fertility treatment and delay attempts to conceive.

“Dr. Chen and the CCRM Fertility of New Jersey team are leaders in reproductive medicine, and we are proud that they performed the first commercial Juveena case,” said John Nealon, President and CEO of Rejoni. “Clinicians have told us that recurrent adhesions are one of the most frustrating problems in reproductive surgery. Our goal is to give surgeons a purpose-built, evidence-based tool that helps protect the result of their work.”

The procedure represents the first commercial use of the technology following FDA approval as Rejoni begins introducing the system into clinical practice.

Leave A Reply

Please enter your comment!
Please enter your name here